S100B and depressive symptom measurement: The present study demonstrated that OA patients with MDD showed significantly changed serum BDNF, VEGF, and S100B and significant associations of these neurotrophins with depression and pain assessments, which suggested that these indicators may be potential biomarkers to identify MDD in OA patients.